Evidence map›Paper›PMID 42474029›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer.

Wei Jiang, Yi Wang, Xiaohang Lu, Qianlan Yao, Libing Xiang, Xu Cai, Xiaoyu Tu, Shaoxian Tang, Ying Xu, Yufan Cheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wei JiangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Yi WangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Xiaohang LuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Qianlan YaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Libing XiangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xu CaiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xiaoyu TuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Shaoxian TangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ying XuSchool of Medicine, Southern University of Science and Technology, Shenzhen, China.
Yufan ChengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liming ShenCollege of Life Science and Oceanography, Shenzhen University, Shenzhen, China.
Huijuan YangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Funding

National Natural Science Foundation of China T2350010National Natural Science Foundation of China: 82503292Shanghai Municipal Commission of Science and Technology: 25ZR1402079Shanghai Shenkang Hospital Development Center
6 · The paper itself

Abstract

Neoadjuvant chemotherapy (NACT) is a standard treatment for high-grade serous ovarian cancer (HGSOC), yet determinants of therapeutic response remain incompletely defined. Here, multi-omics analysis of 102 tumor samples revealed that NACT reshapes the tumor microenvironment, enhancing B- and NK-cell infiltration and activating antigen presentation and BCR/TCR signaling pathways. Notably, Nab-paclitaxel outperformed paclitaxel in promoting B cell-mediated humoral immunity. Unsupervised clustering identifies two biologically distinct subtypes: an immune-active chemotherapy response score (CRS)-high subtype characterized by CD19

Indexed as

CD19+ B cellshigh‐grade serous ovarian cancermulti‐omics analysisNDUFA8neoadjuvant chemotherapy response

Identifiers

PMID42474029
PMCPMC13383156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.